Background: Despite advances in treatment, patients with inflammatory bowel dis-
| INTRODUCTION

Inflammatory Bowel Disease (IBD), including ulcerative colitis (UC)
and Crohn's disease (CD), are chronic, gastrointestinal conditions associated with significant morbidity and healthcare utilisation. [1] [2] [3] By recent estimates, IBD accounts for approximately 1.89 million outpatient visits per year and is the 8th leading physician diagnosis for gastrointestinal disorders in out-patient clinics in the United States (including primary, secondary and tertiary care). [4] [5] [6] Given the chronic, relapsing and remitting nature of both UC and CD, these illnesses are associated with high rates of emergency department (ED) visits, hospitalisations, and surgeries. 7, 8 As a result, with over 1.6 million Americans affected by IBD, the public health burden of these conditions is significant and estimated total annual direct health care costs are as high as $6.3 billion in the United States (US) alone. 9, 10 The ED represents an important, but costly, healthcare resource for UC patients per 100 persons. 11 Female gender, younger age and
Medicaid insurance were associated with more frequent visits to the ED. 11 Studies have also shown an overall increase in the trend of IBD-related ED visits between 1994 and 2005, with an overrepresentation of young, self-paying patients with CD presenting to the ED. 6 Most of the available information on healthcare costs and utilisation associated with IBD has come from data collected in the 1990s
and early 2000s. Since that time, the use of biological agents has expanded significantly, which may affect the above-mentioned costs and statistics related to IBD. For example, recent single-centre studies have reported a decrease in IBD related ED visits, surgeries and hospitalisations with use of anti-tumour-necrosis factor agents. 12, 13 One study using data from the National Emergency Department Sample (NEDS) from 2009 to 2011 reported an increase in ED visits, a decrease in IBD-related hospitalisations, and stable IBD-related ED charges, despite an increase in overall ED charges in those years. 14 The current study aims to provide trends in ED visits and EDassociated costs for patients presenting with a primary diagnosis of IBD between 2006 and 2014 using the NEDS. Secondary aims include comparing trends between CD and UC, and evaluating clinical, demographic and lifestyle variables as predictors of hospital admission following IBD-related ED visits. respectively) compared to private insurance and Medicaid (Table 1 and Table 2 ).
| ME TH ODS
The pattern seen in payer distribution for IBD-related ED visits in terms of both number (Table 1 ) and rate per 100 000 (Table 2) also applies to CD and UC individually. In both cases, the greatest percent increase in rate between years was in Medicaid (51.8% and 93.4%, respectively) and Other/Uninsured (44.3% and 66.9%, respectively) ( Figure 2 ). Additional information on primary payer for CD and UC can be found in Table 1 .
| Surgeries after admission from the ED
The rates of surgery in IBD patients admitted to the hospital from the ED decreased from 9.1% of all ED visits in 2006 to 5.6% of all ED visits in 2014. Chi-square revealed that this was a significant difference (P < 0.001).
UC patients admitted to the hospital from the ED had a higher rate of surgery than CD patients in both years. In 2006, 13.4% of all ED visits for UC underwent surgery compared to 7.2% of all ED visits for CD. In 2014, 7.8% of all ED visits for UC had surgical procedures compared to 4.5% of all ED visits for CD (Table 1 ).
| Predictors of IBD in-patient admissions from the ED
Overall, the rate of IBD-related in-patient admissions from the ED decreased 12.1% in the study period (from 64.7% in 2006 to 52.6% in 2014), table 1. Chi-square analysis revealed that this was a significant decrease (P < 0.001). In univariate analysis, all variables in Table 1 were significant at P < 0.001 and, thus, were entered into multivariable analyses for each year. Due to collinearity, region was 2014 POR = 0.96, both P < 0.001) ( Table 3) . Table 4 
| DISCUSSION
The results of this study show several important trends using a nationally representative sample of IBD-related visits to the ED from 2006 to 2014 in the US. Overall, the number of ED visits with a pri- which found a 38% increase in ED visits for IBD from 2006 to 2012. 18 Better utilisation of ambulatory and urgent care services, introduction of biologics in the late 1990s, more aggressive treatment goals of mucosal healing and deep remission, and increased access to maintenance healthcare could explain the decrease in the rate of ED visits over the last 2 decades. For example, between 2007 and 2015, the proportions of patients using biologics, which have been associated with improved medical outcomes, 19 increased from 22% to 44% in CD and 5%-16% in UC. 20 However, despite the lower rate of increase in ED visits due to IBD in recent years, the overall number of ED visits due to IBD continues to rise, which may be attributable to a variety of factors. Though increased access to healthcare might explain the lower rate of increase in ED visits for IBD, high healthcare costs may simultaneously contribute to the continued increase in rate of IBD ED visits. In addition, despite the improvement in medical management of IBD, the rate of prescription of narcotics in these patients has not significantly changed between
2003 and 2011 and opiate use has been shown to be an independent predictor of ED utilisation among IBD patients.
21,22
The incidence of IBD appears to be rising worldwide. [23] [24] [25] In the US, data from The Rochester Epidemiology Project has demon- In the current study, the 18-44 year age group had the highest rate of IBD-related ED visits in both 2006 and 2014, a finding consistent with other studies. 7 This disproportionate trend may be explained, in part, by the fact that younger patients are more likely to have newer diagnoses and potentially more severe disease compared with older individuals. 7, 8 Indeed, it has previously been shown that patients who have had IBD for less than 5 years have the highest rates of utilisation of healthcare resources compared to people who have had IBD for a longer time and those without IBD. 7 Younger patients with IBD are also more likely to be non-adherent to treatment regimens compared to older patients which could also contribute to higher ED visits. Uninsured patients, self-pay, or patients with 'other' insurance also showed a significantly higher increase in IBD-related ED visits of about 52% over the study period. This pattern was the same when looking at CD and UC separately. Kappelman et al also showed that despite similar numbers of out-patient visits, IBD patients with Medicaid insurance were more likely to visit an ED than those with commercial insurance, 11 which may be due to perceived barriers to out-patient services rather than differences in patient-perceived acuity. 30 Improving out-patient access and minimising barrier to ambulatory healthcare for Medicaid patients might minimise the health care burden due to ED visits among these patients.
There were also significant regional differences in IBD ED visits, 14 and that although a higher proportion of female and younger patients typically present to the ED for IBD care, 11 they are less likely to be hospitalised after those visits when compared to males and older patients. 14 Reasons for higher hospitalisation rates in UC are likely multifactorial and warrant further research. Our findings are consistent with the finding that UC patients admitted from the ED had higher surgery rates than CD patients admitted from the ED, which may indicate that the patients with UC presented to the ED with more severe disease or more complications compared to CD patients in the ED.
Finally, we found that IBD patients in the ED with a secondary diagnosis of tobacco use were significantly more likely to be admitted to the hospital in both 2006 and in 2014, which held true for both CD and for UC patients. This is interesting in light of research regarding the opposing effects of smoking on CD compared to UC, where smoking is detrimental to patients with CD but can be protective in those with UC. [35] [36] [37] In the current study, the likelihood of inpatient admission in those with secondary diagnosis of tobacco use decreased for both CD and UC from 2006 to 2014, though the odds ratios were higher for CD compared to UC in both years. One recent study reported reduced corticosteroid utilisation among smokers with UC, but no reductions in surgery or hospitalisation rates. 38 It is possible that tobacco use is associated with other comorbidities, which could impact likelihood of in-patient admissions, even among those with UC. Additional inquiry is warranted in this area.
There are several important limitations to this study. First, we do not include the ambulatory trends or hospitalisation-related costs for IBD-related care, and thus cannot make comparisons with the rise in ED visits and costs. Second, the data set utilised here includes data from 950 hospitals, and coding/reimbursement practices may vary among each institution and/or by region. Third, this study included only ED visits in which IBD was the primary diagnosis, and may underestimate the number of ED visits if there were visits in which IBD was not the primary discharge diagnosis. Fourth, the area under the ROC for our predictive models did not suggest an ideal fit for our data. This was not unexpected, however, as our model was 
